Equillium reported second quarter 2026 financial results with a net loss of $4.7 million, or $(0.04) per share, compared to a $5.7 million loss in the prior year period. Cash and cash equivalents totaled $57.2 million as of June 30, 2026, which management believes will fund operations into 2029. The company announced that its Phase 1 proof-of-mechanism study for EQ504 is expected to initiate in the fourth quarter of 2026, with topline data anticipated approximately six months later. Equillium operates as a clinical-stage biotechnology innovator developing therapies for severe autoimmune and inflammatory disorders.